Literature DB >> 6403144

Erythrocytapheresis in idiopathic haemochromatosis.

D Conte, L Brunelli, A Bozzani, L Tidone, M Quatrini, P A Bianchi.   

Abstract

Entities:  

Mesh：

Year:  1983        PMID： 6403144      PMCID： PMC1547308          DOI： 10.1136/bmj.286.6369.939

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  5 in total

1.  Continuous subcutaenous administration of deferoxamine in patients with iron overload.

Authors:  R D Propper; B Cooper; R R Rufo; A W Nienhuis; W F Anderson; H F Bunn; A Rosenthal; D G Nathan
Journal:  N Engl J Med       Date:  1977-08-25       Impact factor: 91.245

2.  Treatment of primary hemochromatosis with deferoxamine.

Authors:  N Young; W Henry; A W Nienhuis
Journal:  JAMA       Date:  1979-03-16       Impact factor: 56.272

Review 3.  Perspectives in iron metabolism.

Authors:  C A Finch; H Huebers
Journal:  N Engl J Med       Date:  1982-06-24       Impact factor: 91.245

4.  Reassessment of the use of desferrioxamine B in iron overload.

Authors:  R D Propper; S B Shurin; D G Nathan
Journal:  N Engl J Med       Date:  1976-06-24       Impact factor: 91.245

5.  Long term results of venesection therapy in idiopathic haemochromatosis.

Authors:  A Bomford; R Williams
Journal:  Q J Med       Date:  1976-10
  5 in total
  1 in total

1.  A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemochromatosis.

Authors:  Eva Rombout-Sestrienkova; Bjorn Winkens; Marian van Kraaij; Cees Th B M van Deursen; Mirian C H Janssen; Alexander M J Rennings; Dorothea Evers; Jean-Louis Kerkhoffs; Ad Masclee; Ger H Koek
Journal:  J Clin Apher       Date:  2020-12-24       Impact factor: 2.821
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.